TALPHERA, INC.

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies administered in medically supervised clinical settings. The company's pipeline centers on nafamostat-based formulations targeting anticoagulation and other therapeutic applications. Its lead product candidate, Niyad, is a lyophilized nafamostat formulation under investigational device exemption status for use as an anticoagulant in extracorporeal circuits. The company is also developing LTX-608, an intravenous nafamostat formulation being investigated for multiple indications including antiviral applications, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis.

Beyond its nafamostat program, Talphera is developing Fedsyra and a phenylephrine ready-to-use pre-filled syringe product candidate. These formulations target the medically supervised therapy market segment. The company was rebranded from AcelRx Pharmaceuticals, Inc. to Talphera, Inc. in January 2024, reflecting a strategic shift in its development focus.

The company operates with approximately 13 full-time employees and is headquartered in San Mateo, California. Talphera was incorporated in Delaware in 2005 and is listed on Nasdaq, though current revenue generation appears limited as the pipeline consists primarily of investigational stage candidates.